1. |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021, 7(1): 6.
|
2. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
3. |
Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology, 2017, 152(8): 1954-1964.
|
4. |
Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology, 2013, 57(4): 1426-1435.
|
5. |
Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol, 2013, 58(4): 724-729.
|
6. |
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology, 2018, 68(2): 723-750.
|
7. |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
|
8. |
Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology, 2018, 154(6): 1706-1718.
|
9. |
Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 2009, 30(1): 37-47.
|
10. |
Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol, 2017, 3(4): 456-463.
|
11. |
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版). 中华外科杂志, 2022, 60(4): 273-309.
|
12. |
Radiology ACO. CT/MRI liver imaging reporting and data system version 2018. Available at: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf.
|
13. |
International Consensus Group for Hepatocellular Neoplasiathe. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology, 2009, 49(2): 658-664.
|
14. |
中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版). 临床肝胆病杂志, 2015, 31(6): 833-839.
|
15. |
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536.
|
16. |
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557-560.
|
17. |
Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med, 2002, 21(4): 589-624.
|
18. |
Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol, 2006, 59(12): 1331-1332.
|
19. |
Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol, 2005, 58(10): 982-990.
|
20. |
Riley RD, Abrams KR, Sutton AJ, et al. Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Med Res Methodol, 2007, 7: 3.
|
21. |
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 2005, 58(9): 882-893.
|
22. |
Whang S, Choi MH, Choi JI, et al. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol, 2020, 30(8): 4150-4163.
|
23. |
Vietti Violi N, Lewis S, Liao J, et al. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. Eur Radiol, 2020, 30(11): 6003-6013.
|
24. |
Park HJ, Jang HY, Kim SY, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol, 2020, 72(4): 718-724.
|
25. |
Kim JS, Lee JK, Baek SY, et al. Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdom Radiol (NY), 2020, 45(1): 211-219.
|
26. |
Chan MV, McDonald SJ, Ong YY, et al. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp, 2019, 3(1): 49.
|
27. |
Brunsing RL, Chen DH, Schlein A, et al. Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiol Imaging Cancer, 2019, 1(2): e190010.
|
28. |
Tillman BG, Gorman JD, Hru JM, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol, 2018, 73(5): 485-493.
|
29. |
McNamara MM, Thomas JV, Alexander LF, et al. Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data-a pilot study. Abdom Radiol (NY), 2018, 43(10): 2686-2692.
|
30. |
Han S, Choi JI, Park MY, et al. The diagnostic performance of liver MRI without intravenous contrast for detecting hepatocellular carcinoma: a case-controlled feasibility study. Korean J Radiol, 2018, 19(4): 568-577.
|
31. |
Sutherland T, Watts J, Ryan M, et al. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. J Med Imaging Radiat Oncol, 2017, 61(1): 34-39.
|
32. |
Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY), 2017, 42(1): 179-190.
|
33. |
Marks RM, Ryan A, Heba ER, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol, 2015, 204(3): 527-535.
|
34. |
Jalli R, Jafari SH, Sefidbakht S, et al. Comparison of the accuracy of DWI and ultrasonography in screening hepatocellular carcinoma in patients with chronic liver disease. Iran J Radiol, 2015, 12(1): e12708.
|
35. |
Kim YK, Kim YK, Park HJ, et al. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magn Reson Imaging, 2014, 32(6): 610-618.
|
36. |
王聪, 郭然, 师丹丹, 等. 肝脏特异性对比剂MRI优化序列在高风险人群中筛查小肝癌的价值研究. 磁共振成像, 2021, 12(9): 20-24.
|
37. |
Enomoto S, Tamai H, Shingaki N, et al. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int, 2011, 5(2): 730-737.
|
38. |
Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol, 1998, 170(4): 1005-1013.
|
39. |
Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol, 2008, 18(9): 1937-1952.
|
40. |
Liu X, Zou L, Liu F, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One, 2013, 8(8): e70896.
|
41. |
Andersson KL, Salomon JA, Goldie SJ, et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol, 2008, 6(12): 1418-1424.
|
42. |
Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol, 2017, 8(6): e101.
|
43. |
Lima PH, Fan B, Bérubé J, et al. Cost-utility analysis of imaging for surveillance and diagnosis of hepatocellular carcinoma. AJR Am J Roentgenol, 2019, 213(1): 17-25.
|
44. |
Rao SX, Wang J, Wang J, et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium. J Dig Dis, 2019, 20(2): 54-61.
|
45. |
Brunsing RL, Fowler KJ, Yokoo T, et al. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Res, 2020, 6: 59.
|
46. |
Ramalho J, Ramalho M. Gadolinium deposition and chronic toxicity. Magn Reson Imaging Clin N Am, 2017, 25(4): 765-778.
|
47. |
Cerny M, Bergeron C, Billiard JS, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology, 2018, 288(1): 118-128.
|
48. |
姚刚, 曹峻, 谷昊, 等. 腹腔镜与开腹肝切除术比较治疗肝癌的Meta分析. 中国循证医学杂志, 2013, 13(5): 588-595.
|